Assessment of myocardial infarction in mice by late gadolinium enhancement MR imaging using an inversion recovery pulse sequence at 9.4T.

PubWeight™: 0.99‹?› | Rank: Top 15%

🔗 View Article (PMC 2244610)

Published in J Cardiovasc Magn Reson on January 24, 2008

Authors

Catherine Chapon1, Amy H Herlihy, Kishore K Bhakoo

Author Affiliations

1: Stem Cell Imaging, MRC Clinical Sciences Centre, Hammersmith Hospital, Imperial College London, UK. catherine.chapon@univ-angers.fr

Articles cited by this

Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation (1999) 11.04

An improved MR imaging technique for the visualization of myocardial infarction. Radiology (2001) 7.45

Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation (2001) 2.73

Simultaneous evaluation of infarct size and cardiac function in intact mice by contrast-enhanced cardiac magnetic resonance imaging reveals contractile dysfunction in noninfarcted regions early after myocardial infarction. Circulation (2004) 2.46

Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation (2001) 2.41

Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation (2002) 2.40

Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR (1984) 2.30

Impact of anesthesia on cardiac function during echocardiography in mice. Am J Physiol Heart Circ Physiol (2002) 2.27

Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation (2003) 1.99

Fast, high-resolution in vivo cine magnetic resonance imaging in normal and failing mouse hearts on a vertical 11.7 T system. J Magn Reson Imaging (2003) 1.97

Reproducibility of chronic and acute infarct size measurement by delayed enhancement-magnetic resonance imaging. J Am Coll Cardiol (2006) 1.94

In vivo assessment of absolute perfusion and intracapillary blood volume in the murine myocardium by spin labeling magnetic resonance imaging. Magn Reson Med (2005) 1.31

Myocardial infarction: optimization of inversion times at delayed contrast-enhanced MR imaging. Radiology (2004) 1.27

Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol (2006) 1.25

Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits. J Am Coll Cardiol (2002) 1.02

Multi-contrast delayed enhancement provides improved contrast between myocardial infarction and blood pool. J Magn Reson Imaging (2005) 0.97

Magnetic resonance imaging of coronary arteries and heart valves in a living mouse: techniques and preliminary results. J Magn Reson (2000) 0.90

Tissue edema does not change gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)-enhanced T1 relaxation times of viable myocardium. J Magn Reson Imaging (2005) 0.87

Assessment of myocardial viability in rats: Evaluation of a new method using superparamagnetic iron oxide nanoparticles and Gd-DOTA at high magnetic field. Magn Reson Med (2004) 0.87

The potential of contrast-enhanced magnetic resonance imaging for predicting left ventricular remodeling. J Magn Reson Imaging (2002) 0.86

High frame rate echocardiography: 2D or not 2D? Eur J Echocardiogr (2001) 0.79

Articles by these authors

Natural history of brain lesions in extremely preterm infants studied with serial magnetic resonance imaging from birth and neurodevelopmental assessment. Pediatrics (2006) 2.43

Magic angle effects in MR neurography. AJNR Am J Neuroradiol (2004) 1.73

Magnetic resonance imaging of the knee with ultrashort TE pulse sequences. Magn Reson Imaging (2004) 1.30

Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug Chem (2007) 1.13

Manganese-enhanced magnetic resonance imaging (MEMRI) without compromise of the blood-brain barrier detects hypothalamic neuronal activity in vivo. NMR Biomed (2006) 1.13

In vivo measurements of T1 relaxation times in mouse brain associated with different modes of systemic administration of manganese chloride. J Magn Reson Imaging (2005) 1.12

Homing of stem cells to sites of inflammatory brain injury after intracerebral and intravenous administration: a longitudinal imaging study. Stem Cell Res Ther (2010) 1.09

MR imaging assessment of myelination in the very preterm brain. AJNR Am J Neuroradiol (2002) 1.08

Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun (2006) 1.07

High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol (2005) 1.04

An in vivo multimodal imaging study using MRI and PET of stem cell transplantation after myocardial infarction in rats. Mol Imaging Biol (2008) 1.01

Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage (2008) 0.93

The temporal sequence of gut peptide CNS interactions tracked in vivo by magnetic resonance imaging. J Neurosci (2007) 0.86

T2 relaxation values in the developing preterm brain. AJNR Am J Neuroradiol (2003) 0.85

Tuning sub-10 nm single-phase NaMnF3 nanocrystals as ultrasensitive hosts for pure intense fluorescence and excellent T1 magnetic resonance imaging. Chem Commun (Camb) (2012) 0.84

Generic method for imaging transgene expression. Magn Reson Med (2005) 0.83

Design and synthesis of polymer-functionalized NIR fluorescent dyes--magnetic nanoparticles for bioimaging. ACS Nano (2013) 0.83

The human mirror system: a motor resonance theory of mind-reading. Brain Res Rev (2007) 0.83

A metabonomic analysis of organ specific response to USPIO administration. Biomaterials (2011) 0.83

Bimodal magnetic-fluorescent probes for bioimaging. Microsc Res Tech (2010) 0.83

Brain damage results in down-regulation of N-acetylaspartate as a neuronal osmolyte. Neuromolecular Med (2003) 0.81

Gadolinium oxide ultranarrow nanorods as multimodal contrast agents for optical and magnetic resonance imaging. Langmuir (2010) 0.81

Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. J Nucl Med (2013) 0.79

The combined effects on neuronal activation and blood-brain barrier permeability of time and n-3 polyunsaturated fatty acids in mice, as measured in vivo using MEMRI. Neuroimage (2010) 0.78

Contrast-enhanced magic-angle MR imaging of the Achilles tendon. AJR Am J Roentgenol (2002) 0.78

Imaging molecular and cellular events in transplantation. Transplantation (2006) 0.77

Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents. Am J Nucl Med Mol Imaging (2013) 0.76

Molecular targeting of breast cancer: imaging and therapy. Curr Pharm Biotechnol (2011) 0.76

"Smart" theranostic lanthanide nanoprobes with simultaneous up-conversion fluorescence and tunable T1-T2 magnetic resonance imaging contrast and near-infrared activated photodynamic therapy. Nanoscale (2014) 0.76

A comparison of PET imaging agents for the assessment of therapy efficacy in a rodent model of glioma. Am J Nucl Med Mol Imaging (2013) 0.75

Synthesis of a novel 'smart' bifunctional chelating agent 1-(2-[beta,D-galactopyranosyloxy]ethyl)-7-(1-carboxy-3-[4-aminophenyl]propyl)-4,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (Gal-PA-DO3A-NH2) and its Gd(III) complex. Bioorg Med Chem (2007) 0.75